Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Net Margin: 2009-2025

Historic Net Margin for Amicus Therapeutics (FOLD) over the last 15 years, with Sep 2025 value amounting to 10.24%.

  • Amicus Therapeutics' Net Margin rose 1499.00% to 10.24% in Q3 2025 from the same period last year, while for Sep 2025 it was -2.35%, marking a year-over-year increase of 1886.00%. This contributed to the annual value of -10.62% for FY2024, which is 2734.00% up from last year.
  • As of Q3 2025, Amicus Therapeutics' Net Margin stood at 10.24%, which was up 164.84% from -15.79% recorded in Q2 2025.
  • Amicus Therapeutics' 5-year Net Margin high stood at 10.24% for Q3 2025, and its period low was -108.31% during Q1 2022.
  • For the 3-year period, Amicus Therapeutics' Net Margin averaged around -21.03%, with its median value being -17.31% (2025).
  • Per our database at Business Quant, Amicus Therapeutics' Net Margin skyrocketed by 4,807bps in 2021 and then plummeted by 1,082bps in 2022.
  • Quarterly analysis of 5 years shows Amicus Therapeutics' Net Margin stood at -101.37% in 2021, then spiked by 3,795bps to -63.41% in 2022, then skyrocketed by 3,401bps to -29.41% in 2023, then spiked by 3,925bps to 9.85% in 2024, then soared by 1,499bps to 10.24% in 2025.
  • Its last three reported values are 10.24% in Q3 2025, -15.79% for Q2 2025, and -17.31% during Q1 2025.